Aglaia Therapeutics

Aglaia Therapeutics

A biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients.

Launch date
Market cap
-
Enterprise valuation
CAD24—36m (Dealroom.co estimates Sep 2021.)
Villejuif Île-de-France (HQ)
  • Edit
DateInvestorsAmountRound

€4.0m

Seed
Total FundingCAD6.0m

Recent News about Aglaia Therapeutics

Edit